Company News
Cipla Signs Exclusive HER2 ADC License with SBP
Cipla Limited enters exclusive licensing agreement with SBP Group's subsidiary for HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102).
Cipla gains exclusive rights to develop and commercialize the
